- Home
- CVBF vs GERN Comparison
CVBF vs GERN Comparison
Compare CVBF & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVBF
- GERN
- Stock Information
- Founded
- CVBF 1974
- GERN 1990
- Country
- CVBF United States
- GERN United States
- Employees
- CVBF N/A
- GERN N/A
- Industry
- CVBF Major Banks
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- CVBF Finance
- GERN Health Care
- Exchange
- CVBF Nasdaq
- GERN Nasdaq
- Market Cap
- CVBF 3.1B
- GERN 2.5B
- IPO Year
- CVBF N/A
- GERN 1996
- Fundamental
- Price
- CVBF $22.52
- GERN $3.66
- Analyst Decision
- CVBF Hold
- GERN Strong Buy
- Analyst Count
- CVBF 6
- GERN 10
- Target Price
- CVBF $20.80
- GERN $6.95
- AVG Volume (30 Days)
- CVBF 796.5K
- GERN 9.5M
- Earning Date
- CVBF 10-23-2024
- GERN 11-07-2024
- Dividend Yield
- CVBF 3.55%
- GERN N/A
- EPS Growth
- CVBF N/A
- GERN N/A
- EPS
- CVBF 1.42
- GERN N/A
- Revenue
- CVBF $518,203,999.00
- GERN $29,480,000.00
- Revenue This Year
- CVBF N/A
- GERN $30,930.80
- Revenue Next Year
- CVBF $2.34
- GERN $315.72
- P/E Ratio
- CVBF $15.86
- GERN N/A
- Revenue Growth
- CVBF N/A
- GERN 9199.68
- 52 Week Low
- CVBF $15.71
- GERN $1.64
- 52 Week High
- CVBF $23.43
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- CVBF 66.91
- GERN 29.99
- Support Level
- CVBF $18.77
- GERN $3.98
- Resistance Level
- CVBF $23.43
- GERN $4.50
- Average True Range (ATR)
- CVBF 0.64
- GERN 0.21
- MACD
- CVBF 0.21
- GERN -0.05
- Stochastic Oscillator
- CVBF 80.47
- GERN 3.45
About CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.